Tonix Pharmaceuticals (TNXP) Competitors $0.19 +0.03 (+18.75%) (As of 11/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends TNXP vs. PRPH, PWUP, EPRX, GNLX, ME, CASI, FBLG, PMVP, ONCY, and IKNAShould you be buying Tonix Pharmaceuticals stock or one of its competitors? The main competitors of Tonix Pharmaceuticals include ProPhase Labs (PRPH), PowerUp Acquisition (PWUP), Eupraxia Pharmaceuticals (EPRX), Genelux (GNLX), 23andMe (ME), CASI Pharmaceuticals (CASI), FibroBiologics (FBLG), PMV Pharmaceuticals (PMVP), Oncolytics Biotech (ONCY), and Ikena Oncology (IKNA). These companies are all part of the "pharmaceutical products" industry. Tonix Pharmaceuticals vs. ProPhase Labs PowerUp Acquisition Eupraxia Pharmaceuticals Genelux 23andMe CASI Pharmaceuticals FibroBiologics PMV Pharmaceuticals Oncolytics Biotech Ikena Oncology ProPhase Labs (NASDAQ:PRPH) and Tonix Pharmaceuticals (NASDAQ:TNXP) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, profitability, dividends, media sentiment, community ranking, risk, institutional ownership, earnings and analyst recommendations. Does the MarketBeat Community prefer PRPH or TNXP? Tonix Pharmaceuticals received 226 more outperform votes than ProPhase Labs when rated by MarketBeat users. Likewise, 61.93% of users gave Tonix Pharmaceuticals an outperform vote while only 50.00% of users gave ProPhase Labs an outperform vote. CompanyUnderperformOutperformProPhase LabsOutperform Votes11450.00% Underperform Votes11450.00% Tonix PharmaceuticalsOutperform Votes34061.93% Underperform Votes20938.07% Does the media refer more to PRPH or TNXP? In the previous week, ProPhase Labs and ProPhase Labs both had 6 articles in the media. Tonix Pharmaceuticals' average media sentiment score of 0.28 beat ProPhase Labs' score of -0.39 indicating that Tonix Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ProPhase Labs 0 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Tonix Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more volatility and risk, PRPH or TNXP? ProPhase Labs has a beta of -0.1, indicating that its share price is 110% less volatile than the S&P 500. Comparatively, Tonix Pharmaceuticals has a beta of 2.06, indicating that its share price is 106% more volatile than the S&P 500. Which has preferable valuation and earnings, PRPH or TNXP? ProPhase Labs has higher revenue and earnings than Tonix Pharmaceuticals. ProPhase Labs is trading at a lower price-to-earnings ratio than Tonix Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioProPhase Labs$44.38M0.41-$16.78M-$1.26-0.61Tonix Pharmaceuticals$7.77M3.36-$116.66M-$52.740.00 Do analysts recommend PRPH or TNXP? ProPhase Labs presently has a consensus target price of $11.00, indicating a potential upside of 1,337.91%. Tonix Pharmaceuticals has a consensus target price of $53.50, indicating a potential upside of 28,057.89%. Given Tonix Pharmaceuticals' higher possible upside, analysts plainly believe Tonix Pharmaceuticals is more favorable than ProPhase Labs.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ProPhase Labs 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Tonix Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is PRPH or TNXP more profitable? ProPhase Labs has a net margin of -217.64% compared to Tonix Pharmaceuticals' net margin of -1,197.86%. ProPhase Labs' return on equity of -62.92% beat Tonix Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets ProPhase Labs-217.64% -62.92% -30.22% Tonix Pharmaceuticals -1,197.86%-163.95%-118.88% Do institutionals & insiders believe in PRPH or TNXP? 9.5% of ProPhase Labs shares are held by institutional investors. Comparatively, 82.3% of Tonix Pharmaceuticals shares are held by institutional investors. 20.7% of ProPhase Labs shares are held by insiders. Comparatively, 0.0% of Tonix Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. SummaryTonix Pharmaceuticals beats ProPhase Labs on 9 of the 16 factors compared between the two stocks. Ad Wyatt Investment ResearchMy #1 Pre IPO Trade for 2025 – NAME and TICKEROne tiny company... Could quickly become "the next SpaceX." It plans to go public on the NASDAQ. And today you can buy Pre-IPO shares for less than $4.00. Get urgent details inside this free report...The Next SpaceX Pre-IPO Get Tonix Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for TNXP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TNXP vs. The Competition Export to ExcelMetricTonix PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$26.08M$6.43B$5.05B$8.82BDividend YieldN/A8.11%5.17%4.07%P/E Ratio0.0010.41123.8917.66Price / Sales3.36243.791,181.4274.22Price / CashN/A22.1633.6632.53Price / Book0.005.474.684.68Net Income-$116.66M$153.61M$119.38M$226.08M7 Day Performance34.56%-4.32%-2.46%-2.03%1 Month Performance5.56%-8.61%-4.07%0.07%1 Year Performance-98.77%28.78%29.77%24.61% Tonix Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TNXPTonix Pharmaceuticals2.9676 of 5 stars$0.19+18.8%$53.50+28,057.9%-98.8%$22.33M$7.77M0.00103Analyst ForecastGap UpHigh Trading VolumePRPHProPhase Labs3.242 of 5 stars$0.77+1.3%$11.00+1,337.9%-82.8%$18.14M$44.38M0.00130PWUPPowerUp AcquisitionN/A$11.50flatN/AN/A$89.30MN/A0.00N/AEPRXEupraxia Pharmaceuticals2.4866 of 5 stars$3.62+11.0%$9.00+148.6%N/A$88.94MN/A0.0029Gap UpHigh Trading VolumeGNLXGenelux1.3298 of 5 stars$2.49+0.4%$18.25+632.9%-76.8%$85.65M$170,000.000.0010Gap UpME23andMe1.2334 of 5 stars$3.15-8.2%$9.40+198.4%-82.6%$84.08M$219.64M0.00770CASICASI Pharmaceuticals3.802 of 5 stars$5.22-2.2%$6.00+14.9%+0.4%$82.56M$33.88M0.00180FBLGFibroBiologics1.729 of 5 stars$2.24-5.9%$12.00+435.7%N/A$82.49MN/A0.0010PMVPPMV Pharmaceuticals2.804 of 5 stars$1.57-1.3%$5.80+269.4%-36.9%$82.28MN/A0.0050ONCYOncolytics Biotech1.2173 of 5 stars$1.00-5.7%$4.00+300.6%-37.2%$81.70MN/A0.0030Analyst RevisionIKNAIkena Oncology3.4984 of 5 stars$1.70+1.2%$3.00+76.5%-0.6%$81.07M$9.16M0.0070 Related Companies and Tools Related Companies ProPhase Labs Alternatives PowerUp Acquisition Alternatives Eupraxia Pharmaceuticals Alternatives Genelux Alternatives 23andMe Alternatives CASI Pharmaceuticals Alternatives FibroBiologics Alternatives PMV Pharmaceuticals Alternatives Oncolytics Biotech Alternatives Ikena Oncology Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:TNXP) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tonix Pharmaceuticals Holding Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tonix Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
